tumorderived exosome programmed death ligand 1 (Exosome Diagnostics)
86
Structured Review
Exosome Diagnostics
tumorderived exosome programmed death ligand 1
Tumorderived Exosome Programmed Death Ligand 1, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+death+1/1+death+exosome+ligand+programmed+tumorderived/pm41864926-805-2-3
Average 86 stars, based on 1 article reviews
Tumorderived Exosome Programmed Death Ligand 1, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+death+1/1+death+exosome+ligand+programmed+tumorderived/pm41864926-805-2-3
Average 86 stars, based on 1 article reviews
tumorderived exosome programmed death ligand 1 - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Expressing:Article Title: Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Article Snippet: Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CARTcells have not shown much success against solid malignancies.. There are several obstacles which diminish the efficacy of CARTcells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor.. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. Dominant Negative Mutation:Article Title: Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Article Snippet: Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CARTcells have not shown much success against solid malignancies.. There are several obstacles which diminish the efficacy of CARTcells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor.. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. Knock-Out:Article Title: Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Article Snippet: Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CARTcells have not shown much success against solid malignancies.. There are several obstacles which diminish the efficacy of CARTcells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor.. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. Blocking Assay:Article Title: Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Article Snippet: Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CARTcells have not shown much success against solid malignancies.. There are several obstacles which diminish the efficacy of CARTcells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor.. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. other:Article Title: The role of heat shock proteins in tumorigenesis and their potential as targets for anti-tumor therapy. Article Snippet: Heat shock proteins (HSPs) are a group of highly conserved proteins that are widely present in eukaryotes and prokaryotes, and their expression are mostly induced by heat shock or stressors.. According to the molecular weight, they mainly includes HSP110, HSP90, HSP70, HSP60, HSP40, and Small HSPs.. Research has found that HSPs and exosomes are present in a variety of tumors and their microenvironments. Article Title: CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Article Snippet: Oxaliplatin is a widely applied anti-cancer drug in clinics for colorectal cancer (CRC) treatment.. Nonetheless, the treatment efficacy is always limited by the acquisition of chemoresistance in cancer cells.. The deregulation of long non-coding RNA (lncRNA) FAL1 has been implicated in the tumorigenesis and progression of different malignancies. Article Title: Plant-derived extracellular vesicles as tools and targets for inflammatory diseases. Article Snippet: Effects of Cell Function Assay:Article Title: Exosome-disrupting peptides for cancer immunotherapy. Article Snippet: Immune checkpoint blockade therapies that target the programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) axis have revolutionized cancer therapy.. These therapies, mainly comprising monoclonal antibodies, can specifically block PD-1/PD-L1 interactions between T cells and cancer cells and thus prevent T cells from resultant exhaustion and inactivation, preserving a strong antitumour immune response.. Several anti-PD-1/PD-L1 antibodies have already been approved by the US Food and Drug Administration and a large number of candidates are in clinical and pre-clinical studies. Inhibition:Article Title: Exosome-disrupting peptides for cancer immunotherapy. Article Snippet: Immune checkpoint blockade therapies that target the programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) axis have revolutionized cancer therapy.. These therapies, mainly comprising monoclonal antibodies, can specifically block PD-1/PD-L1 interactions between T cells and cancer cells and thus prevent T cells from resultant exhaustion and inactivation, preserving a strong antitumour immune response.. Several anti-PD-1/PD-L1 antibodies have already been approved by the US Food and Drug Administration and a large number of candidates are in clinical and pre-clinical studies. Membrane:Article Title: Exosome-disrupting peptides for cancer immunotherapy. Article Snippet: Immune checkpoint blockade therapies that target the programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) axis have revolutionized cancer therapy.. These therapies, mainly comprising monoclonal antibodies, can specifically block PD-1/PD-L1 interactions between T cells and cancer cells and thus prevent T cells from resultant exhaustion and inactivation, preserving a strong antitumour immune response.. Several anti-PD-1/PD-L1 antibodies have already been approved by the US Food and Drug Administration and a large number of candidates are in clinical and pre-clinical studies. In Vivo:Article Title: Exosome-disrupting peptides for cancer immunotherapy. Article Snippet: Immune checkpoint blockade therapies that target the programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) axis have revolutionized cancer therapy.. These therapies, mainly comprising monoclonal antibodies, can specifically block PD-1/PD-L1 interactions between T cells and cancer cells and thus prevent T cells from resultant exhaustion and inactivation, preserving a strong antitumour immune response.. Several anti-PD-1/PD-L1 antibodies have already been approved by the US Food and Drug Administration and a large number of candidates are in clinical and pre-clinical studies. Activation Assay:Article Title: Exosome-based strategies and immunotherapy for skin cancer: mechanisms, challenges, and future directions. Article Snippet: Abbreviations EVs Extracellular vesicles MVBs Multi-vesicular bodies MV Microvesicles DOX Doxorubicin PEG Polyethylene glycol CSCs Cancer stem cells TPL Triptolide TF Tissue factor ICIs Immune checkpoint inhibitors CPIs Checkpoint inhibitors CTLA-4 Cytotoxic-T lymphocytes antigen 4 PD-1 Programmed cell death protein 1 TILs Tumor-infiltrating lymphocytes Tregs Regulatory T cells NK Natural killer APCs Antigen-presenting cells OVs Oncolytic viruses pRb Retinoblastoma protein ACT Adoptive cell therapy Shima Rahmati shimarahmati1987@gmail.com |
